Published online before print March 8, 2007, doi: 10.1161/ATVBAHA.107.141580
© 2007 American Heart Association, Inc.
Thrombosis |
Darbepoetin-Alpha Does Not Promote Microvascular Thrombus Formation in Mice
Role of eNOS-Dependent Protection Through Platelet and Endothelial Cell Deactivation
From the Institute for Experimental Surgery (N.L., B.V.) and the Department of General Surgery (N.L., E.K.), University of Rostock, and the Institute for Clinical & Experimental Surgery (M.D.M.), University of Saarland, Germany.
Correspondence to Brigitte Vollmar, MD, Institute for Experimental Surgery, University of Rostock, Schillingallee 69a, 18055 Rostock, Germany. E-mail brigitte.vollmar{at}med.uni-rostock.de
Objective— Erythropoietin (EPO) treatment has become the standard treatment of renal anemia. Though a link between hematopoiesis-stimulating drugs and thrombosis has not been proven, it is generally assumed that systemic application of EPO and its analogues increases the risk for thrombotic events.
Methods and Results— Here we show in C57BL/6J mice that 4-week treatment with the long-lasting EPO analogue darbepoetin-alpha (DPO) at a dose of 10 µg/kg/week induces a reduction of platelet reactivity using flow cytometry and Western blot analysis of tyrosine-specific platelet phosphorylation. Additionally, immunohistochemistry of endothelial adhesion molecule expression and ELISA of circulating endothelial activation markers demonstrated a reduced endothelial activation. Immunohistochemistry and RT-PCR analysis revealed a significant (P<0.05) increase of eNOS expression. Further, DPO did not exert prothrombogenic effects in a murine intravital microscopic thrombosis model of the cremaster muscle. The role of eNOS in prevention of DPO-mediated microvascular thrombosis is further underlined by a significantly accelerated thrombus formation on DPO treatment in eNOS (–/–) mice.
Conclusion— Thus, DPO-related erythropoiesis with a raised hematocrit is not associated with an increased risk for thrombosis as long as endothelial NO production serves as compensatory mechanism.
EPO treatment is generally assumed to increase the risk for thrombosis. Darbepoetin-alpha (DPO) raised eNOS expression and reduced platelet and endothelial activation without having prothrombogenic effects in vivo. DPO-related erythropoiesis is not associated with an increased risk for thrombosis as long as endothelial NO production serves as compensatory mechanism.
Key Words: endothelium • intravital microscopy • nitric oxide • platelets • thrombosis
This article has been cited by other articles:
 |
|
 |
|
  B. K. Hadland and G. D. Longmore Erythroid-Stimulating Agents in Cancer Therapy: Potential Dangers and Biologic Mechanisms J. Clin. Oncol., September 1, 2009; 27(25): 4217 - 4226. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Sorg, C. Krueger, T. Schulz, M. D. Menger, F. Schmitz, and B. Vollmar Effects of erythropoietin in skin wound healing are dose related FASEB J, September 1, 2009; 23(9): 3049 - 3058. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. M. T. Hare, A. K. Y. Tsui, A. T. McLaren, T. E. Ragoonanan, J. Yu, and C. D. Mazer Anemia and Cerebral Outcomes: Many Questions, Fewer Answers Anesth. Analg., October 1, 2008; 107(4): 1356 - 1370. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. V. d'Uscio and Z. S. Katusic Erythropoietin Increases Endothelial Biosynthesis of Tetrahydrobiopterin by Activation of Protein Kinase B{alpha}/Akt1 Hypertension, July 1, 2008; 52(1): 93 - 99. [Abstract] [Full Text] [PDF]
|
|